Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SMMT advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SMMT's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where SMMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SMMT just turned positive on November 25, 2025. Looking at past instances where SMMT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SMMT entered a downward trend on November 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SMMT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (69.444) is normal, around the industry mean (27.168). P/E Ratio (26.355) is within average values for comparable stocks, (52.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.897). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (334.447).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of novel medicines
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NFJ | 13.05 | 0.23 | +1.79% |
| Virtus Dividend Interest & Premium Strategy Fund | |||
| PSCE | 43.64 | 0.45 | +1.04% |
| Invesco S&P SmallCap Energy ETF | |||
| RND | 30.62 | 0.11 | +0.35% |
| First Trust Bloomberg R&D Leaders ETF | |||
| RSMR | 21.77 | 0.04 | +0.20% |
| FT Vest U.S. Equity Equal Weight Buffer ETF - March | |||
| DBL | 15.37 | -0.04 | -0.26% |
| Doubleline Opportunistic Credit Fund | |||
A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.
| Ticker / NAME | Correlation To SMMT | 1D Price Change % | ||
|---|---|---|---|---|
| SMMT | 100% | +0.39% | ||
| BCDA - SMMT | 70% Closely correlated | +1.40% | ||
| TIL - SMMT | 51% Loosely correlated | +6.51% | ||
| BNTX - SMMT | 51% Loosely correlated | +0.44% | ||
| VBIZF - SMMT | 42% Loosely correlated | N/A | ||
| IDYA - SMMT | 41% Loosely correlated | -0.72% | ||
More | ||||